It has important therapeutic significance for AML patients carrying FLT3 internal tandem duplication mutations (FLT3-ITD) and has been approved for the treatment of relapsed/refractory FLT3-mutated acute myeloid leukemia [40]. The gene discussed is FLT3; the disease is acute myeloid leukemia.